Monaco Asset Management Sam Kodiak Sciences Inc. Transaction History

Monaco Asset Management Sam

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	SELL	$1.4 - $3.24 $158,362 - $366,495	-113,116 Reduced 22.91%	380,610 $1.16 Million
Q3 2023 Nov 07, 2023	BUY	$1.8 - $7.49 $501,489 - $2.09 Million	278,605 Added 129.51%	493,726 $888,000
Q2 2023 Aug 08, 2023	SELL	$4.3 - $9.48 $800,857 - $1.77 Million	-186,246 Reduced 46.4%	215,121 $1.48 Million
Q1 2023 May 11, 2023	BUY	$4.81 - $8.88 $38,484 - $71,048	8,001 Added 2.03%	401,367 $2.49 Million
Q4 2022 Jan 31, 2023	BUY	$6.52 - $8.05 $431,330 - $532,547	66,155 Added 20.22%	393,366 $2.82 Million
Q3 2022 Oct 31, 2022	SELL	$7.57 - $12.5 $1.04 Million - $1.72 Million	-137,587 Reduced 29.6%	327,211 $2.53 Million
Q2 2022 Aug 01, 2022	BUY	$5.04 - $9.48 $1.96 Million - $3.69 Million	389,598 Added 518.08%	464,798 $3.55 Million
Q1 2022 May 09, 2022	BUY	$7.09 - $89.45 $533,168 - $6.73 Million	75,200 New	75,200 $581,000

104

39.8M

7.6K

3.5K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $138M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Monaco Asset Management Sam, based on Form 13F filings with the SEC.

Stay updated on Monaco Asset Management Sam with notifications on news.